
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Understanding the mechanisms of treatment resistance is among the areas of unmet need, says James Brugarolas, MD, PhD.
James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, lists several areas of unmet need in the treatment paradigm for patients with renal cell carcinoma.